Dihexa vs P21
A side-by-side research comparison of Dihexa and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dihexa | P21 |
|---|---|---|
| Full name | Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Allosteric potentiator of HGF/c-Met signaling driving synaptogenesis, dendritic spine formation, and neuronal survival in hippocampal circuits. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | 507.6 Da | ~450 Da |
| Half-life | 6-12 hours | 4-6 hours |
| Bioavailability | Moderate (oral/SubQ) | Moderate (crosses BBB) |
| Typical dose | 10-20 mg (oral) or 2-5 mg (SubQ) | 50-100 mcg/kg |
| Frequency | Daily | Daily |
| Route | Oral or Subcutaneous | Intranasal or Subcutaneous |
Dihexa reported benefits
- Dramatic synaptogenesis
- Memory improvement
- Cognitive restoration potential
- Dendritic spine growth
- HGF/c-Met activation
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.